Comparing the Clinical Results of Idarubicin and Daunorubicin in Treating AML

Objective:Comparing the results of idarubicin and daunorubicin in treating AML.Methods:Randomizing trial comparing idarubicin and daunorubicin in 78 newly diagnosed AML.Results:The two groups are similar in early induced failure(IDA 8.82% vs DNA 11.36%;P 0.01),but on the late induced failure(40 days),the IDA-group is fewer than DNR(11.76% vs 22.73%;P0.01),while the CR is on the contrary(IDA 73.53%,DNR 56.82%;P0.01).Conclusion:As the therapy containing idarubicin gains advantage over that of containing daunorubicin in CR idarubicin can be the first eptional anthracycline in treating the patients of AML.